🔗 Visit the ClinicalTrials.gov page for NCT02312557
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. | Clin Med Insights Oncol | 2016 | 0.83 |
| 2 | New drugs in prostate cancer. | Prostate Int | 2016 | 0.80 |
| 3 | Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. | Oncoimmunology | 2016 | 0.79 |
| 4 | A primer on tumour immunology and prostate cancer immunotherapy. | Can Urol Assoc J | 2016 | 0.79 |
| 5 | Immunotherapy for prostate cancer: False promises or true hope? | Cancer | 2016 | 0.78 |
| 6 | Androgen pathway resistance in prostate cancer and therapeutic implications. | Expert Opin Pharmacother | 2015 | 0.77 |
| 7 | Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? | Oncol Rev | 2016 | 0.76 |
| 8 | Immune Therapy for Prostate Cancer. | Cancer J | 2016 | 0.76 |